Prognostic Value of p53 and Ki-67 Expression in Intermediate-risk Patients With Nonmuscle-invasive Bladder Cancer Receiving Adjuvant Intravesical Mitomycin C Therapy-Reference-Cited by-同舟云学术

Prognostic Value of p53 and Ki-67 Expression in Intermediate-risk Patients With Nonmuscle-invasive Bladder Cancer Receiving Adjuvant Intravesical Mitomycin C Therapy

Published:2010-08 Issue:2 Volume:76 Page:512.e1-512.e7
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Seo Ho Kyung,Cho Kang Su,Chung Jinsoo,Joung Jae Young,Park Weon Seo,Chung Moon Kee,Lee Kang Hyun

Funder

National Cancer Centre

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence;Millan-Rodriguez;J Urol,2000

2. Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer;Horvath;BJU Int,2009

3. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers;Habuchi;Urology,2005

4. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors;Cordon-Cardo;Cancer Res,1997

5. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder;Serth;Br J Cancer,1995

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Implementing Paris System on Diagnostic Precision and Management of Urinary Bladder Neoplasms;Indian Journal of Surgical Oncology;2024-01-04

2. The Clinical Value of Apparent Diffusion Coefficient of Readout Segmentation of Long Variable Echo Trains and Correlation With Ki-67 Expression in Distal Rectal Cancer;Journal of Computer Assisted Tomography;2023-12-18

3. Predictive Biomarkers in the Management of Bladder Cancer: Perspectives in an Evolving Therapeutic Landscape;Société Internationale d’Urologie Journal;2022-07-15

4. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer;Mini-Reviews in Medicinal Chemistry;2020-07-23

5. Significance of TP53 mutation in bladder cancer disease progression and drug selection;PeerJ;2019-12-16